Josephine van Dongen

Chapter 3 76 32. LeinoT, Ollgren J, Stromberg N, Elonsalo U. Evaluation of the intussusception risk after pentavalent rotavirus vaccination in Finnish infants. PLoS One . 2016;11(3):e0144812. 33. Stowe J, Andrews N, Ladhani S, Miller E.The risk of intussusception following monovalent rotavirus vaccination in England: a self-controlled case-series evaluation. Vaccine. 2016;34(32):3684–9. 34. Rha B,Tate JE,Weintraub E, Haber P,Yen C, Patel M, Cor tese MM, DeStefano F, Parashar UD. Intussusception following rotavirus vaccination: an updated review of the available evidence. Expert Rev Vaccines. 2014;13(11):1339–48. 35. Oberle D, Jenke AC, von Kries R, Mentzer D, Keller-Stanislawski B. Rotavirus vaccination: a risk factor for intussusception? Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2014;57(2):234–41. 36. Palupi-Baroto R, Lee KJ, Carlin JB, Bines JE. Intussusception in Australia: epidemiology prior to the introduction of rotavirus vaccine. Aust N Z J Public Health . 2015;39(1):11–4. 37. Reyes JF,Wood JG, Beutels P, Macartney K, McIntyre P, Menzies R, Mealing N, Newall AT. Beyond expectations: post-implementation data shows rotavirus vaccination is likely cost- saving in Australia. Vaccine. 2017;35:345–52. 38. Mangen MJ, Bouwknegt M, Friesema IH, Haagsma JA, Kor tbeek LM,Tariq L,Wilson M, van Pelt W, Havelaar AH. Cost-of-illness and disease burden of food-related pathogens in the Netherlands, 2011. Int J Food Microbiol. 2015;196:84–93. 39. Tan-Torres Edejer T, Baltussen R, AdamT, Hutubessy R, Acharya A, Evans DB, Murray CJL.WHO guide to cost-effectiveness analysis. Geneva:World Health Organization; 2003. 40. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. [https://www.nice.org.uk/process/pmg9/chapter/the-appraisal-of- the-evidence-and-structured-decision-making]. 41. Cleemput I, Neyt M,Thiry N, De Laet C, Leys M.Threshold values for costeffectiveness in health care health technology assessment (HTA). Brussels: Belgian Health Care Knowledge Centre; 2008. 42. Neumann PJ, Cohen JT,Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med . 2014;371(9):796–7. 43. Parez N, Giaquinto C, Du Roure C, Mar tinon-Torres F, Spoulou V,Van Damme P,Vesikari T. Rotavirus vaccination in Europe: drivers and barriers. Lancet Infect Dis . 2014;14(5):416–25. 44. Publique HCdlS. Infections à rotavirus : suspension des recommandations de vaccination des nourrissons [rotavirus infections; recommendation for infant vaccination suspended]. In: Avis et rappor ts de HCSP. Paris: Haut Conseil de la Sante Publique (HCSP); 2015. p. 1–5. 45. Pitzer VE, Atkins KE, de Blasio BF,Van Effelterre T, Atchison CJ, Harris JP, Shim E, Galvani AP, Edmunds WJ,Viboud C, et al. Direct and indirect effects of rotavirus vaccination: comparing predictions from transmission dynamic models. PLoS One . 2012;7(8):e42320. 46. CentraalBureau voor de Statistiek. Levensverwachting; geslacht, leeftijd (per jaar en periode van vijf jaren). [http://statline.cbs.nl/Statweb/ 47. Global Health Data Exchange. Perinatal care in the Netherlands 2008. 2008. 48. Brisson M, Sénécal M, Drolet M, Mansi JA. Health-related quality of life lost to ro- tavirus-associated gastroenteritis in children and their parents: a Canadian prospective study. Pediatr Infect Dis J. 2010;29(1):73–5. 49. Jit M, Mangen MJ, Melliez H,YazdanpanahY, Bilcke J, Salo H, Edmunds WJ, Beutels P. An update to “The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe”. Vaccine. 2010;28(47):7457–9.